<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3917">
  <stage>Registered</stage>
  <submitdate>3/05/2013</submitdate>
  <approvaldate>3/05/2013</approvaldate>
  <nctid>NCT01851824</nctid>
  <trial_identification>
    <studytitle>A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy</studytitle>
    <scientifictitle>A PHASE I, OPEN-LABEL, MULTICENTER, 3-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ACENOCOUMAROL IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2012-003706-27</secondaryid>
    <secondaryid>GO28397</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Malignant Melanoma, Neoplasms</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - acenocoumarol
Treatment: drugs - vemurafenib

Experimental: Acenocoumarol + Vemurafenib - 


Treatment: drugs: acenocoumarol
4 mg single oral doses on Days 1 and 23

Treatment: drugs: vemurafenib
960 mg orally bid, 20 days (Days 4-23)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pharmacokinetics of single-dose acenocoumarol under conditions of vemurafenib steady-state exposure: Area under the concentration-time curve (AUC)</outcome>
      <timepoint>Pre-dose and up to 72 hours post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics of single-dose acenocoumarol under conditions of vemurafenib steady-state exposure: Maximum plasma concentration (Cmax)</outcome>
      <timepoint>Pre-dose and up to 72 hours post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics of single-dose acenocoumarol under conditions of vemurafenib steady-state exposure: Time to maximum plasma concentration (Tmax)</outcome>
      <timepoint>Pre-dose and up to 72 hours post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics of single-dose acenocoumarol under conditions of vemurafenib steady-state exposure: Terminal half-life (t1/2)</outcome>
      <timepoint>Pre-dose and up to 72 hours post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics of single-dose acenocoumarol under conditions of vemurafenib steady-state exposure: Apparent clearance (CL/F)</outcome>
      <timepoint>Pre-dose and up to 72 hours post-dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Incidence of Adverse Events and Serious Adverse Events</outcome>
      <timepoint>approximately 1.5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adult patients, 18-70 years of age

          -  Patients with either unresectable Stage IIIc or IV BRAFV600 mutation-positive
             metastatic melanoma or other malignant BRAFV600 mutation-positive tumor type and who
             have no acceptable standard treatment options

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

          -  Full recovery from any major surgery or significant traumatic injury at least 14 days
             prior to the first dose of study treatment

          -  Adequate hematologic and end organ function

          -  Female patients of childbearing potential and male patients with female partners of
             childbearing potential must agree to use 2 effective methods of contraception as
             defined by protocol during the course of the study and for at least 6 months after
             completion of study treatment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of Day 1

          -  Prior anti-cancer therapy within 28 days (6 weeks for nitrosureas or mitocyn C, or 14
             days for hormonal therapy or kinase inhibitors) before the first dose of study
             treatment Day 1

          -  Palliative radiotherapy within 2 weeks prior to first dose of study treatment Day 1

          -  Experimental therapy within 4 weeks prior to first dose of study treatment Day 1

          -  History of clinically significant cardiac or pulmonary dysfunction, including current
             uncontrolled Grade &gt;/=2 hypertension or unstable angina

          -  Current Grade &gt;/=2 dyspnea or hypoxia or need for oxygen supplementation

          -  History of myocardial infarction within 6 months prior to first dose of study
             treatment

          -  Active central nervous system lesions (i.e. participants with radiographically
             unstable, symptomatic lesions)

          -  History of bleeding or coagulation disorders

          -  Allergy or hypersensitivity to vemurafenib or acenocoumarol formulations

          -  History of malabsorption or other condition that would interfere with the enteral
             absorption of study treatment

          -  Participants with VKORC1 mutations (1639G&amp;#8594;A, 1173C&amp;#8594;T) in either one allele
             (heterozygous)or two alleles (homozygous)

          -  Participants with CYP2C9*3 mutations in either one allele (heterozygous) or two
             alleles (homozygous)

          -  History of clinically significant liver disease (including cirrhosis), current alcohol
             abuse, or active hepatitis B or hepatitis C virus infection

          -  Human immunodeficiency virus (HIV) infection requiring antiretroviral treatment, or
             AIDS-related illness

          -  Pregnant or lactating women</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>9</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital> - Wodonga</hospital>
    <postcode>3690 - Wodonga</postcode>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Buxtehude</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Crete</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastricht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This open-label, multicenter, 3-period, fixed-sequence study will evaluate the effect of
      multiple doses of vemurafenib on the pharmacokinetics of a single dose of acenocoumarol in
      participants with BRAFV600 mutation-positive metastatic malignancies. Participants will
      receive a single dose of acenocoumarol 4 mg orally on Day 1 and Day 23, vemurafenib 960 mg
      orally twice daily on Days 4-26. After completion of pharmacokinetic assessments on Day 26,
      eligible participants will have the option to continue treatment with vemurafenib as part of
      an extension study (GO28399 [NCT01739764]).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01851824</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>